Search the Newsreel

Cellectis earnings beat by $0.04, revenue fell short of estimates

Cellectis (NASDAQ: CLLS) reported Q2 EPS of $-0.220, beating analyst estimates by $0.04, but revenue of $6.9M fell short of the $10.97M consensus. The company's stock is down 30.130% in the last three months but up 1.130% over the last year. The article also …

AbCellera Biologics Inc. $ABCL Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 36.8% in the first quarter, selling 878,600 shares but still retaining 1.51 million shares valued at $5.27 million. This comes as AbCellera reported weaker-than-expected quarterly results, missing both earnings per share …

FuelCell Energy Inc. stock falls Thursday, underperforms market

FuelCell Energy Inc. (FCEL) stock fell by 3.88% on Thursday, closing at $20.32. This performance underperformed the broader market, as the NASDAQ Composite Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for FuelCell Energy shares.

Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million

Celldex reported a wider net loss of $

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M

Celldex Therapeutics, Inc. (CLDX) announced its Q2 revenue was $0.0M, as detailed in an earnings flash from MarketScreener. The company, a clinical-stage biotechnology firm, focuses on developing antibody-based therapeutics for inflammatory, allergic, autoimmune, and other diseases. Recent news also included adjustments to price targets …

[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report

Cellectis Q2: $169M Cash, FDA RMAT for Lasme-cel | CLLS Stock News

Cellectis reported its Q2 2026 financial results, highlighting $169 million in cash, cash equivalents, and fixed-term deposits, providing a runway into Q4 2027. The company announced that its investigational therapy, lasme-cel, received FDA RMAT designation for relapsed or refractory B-ALL based on Phase 1 …

Calf-health company ImmuCell schedules Aug. 14 results webcast

ImmuCell (Nasdaq: ICCC) will report its unaudited financial results for the quarter ended June 30, 2026, after market close on August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results, …

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell Corporation will announce its unaudited financial results for the quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results. …

Millicom (TIGO) boosts 2026 EFCF guidance and dividends

Millicom International Cellular S.A. (TIGO) has raised its full-year 2026 Equity Free Cash Flow (EFCF) guidance to around $1.1 billion, up from at least $900 million, and lowered its year-end leverage target to below 2.5x. This improved outlook follows strong first-half 2026 performance, marked …

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) reported a Q2 loss of $0.94 per share, which was better than the Zacks Consensus Estimate of a $1.04 loss, but missed revenue estimates significantly, posting only $0.02 million against an expectation of $0.73 million. Despite the revenue miss, the company's …

Cellectis Reports 105.6M Voting Rights as of July 31

Cellectis (CLLS) has disclosed its monthly share capital and voting rights as of July 31, 2026, reporting 100,701,207 shares outstanding and 105,554,794 voting rights. This disclosure is in accordance with Article 223-16 of the French financial markets authority. The company's shares are listed on …

Millicom International Cellular S.A. (TIGO) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for Millicom International Cellular S.A. (TIGO). It shows the current stock price, which is $106.39, up $14.60 (15.91%). The article also mentions the absence of analyst ratings and earnings information for the company, while also including …

TIGO Stock Pops As UBS Lifts Target Ahead Q2 Call

Millicom International Cellular S.A. (TIGO) shares surged by 15.75% after UBS raised its price target to $100 from $90, while maintaining a Neutral rating. The stock's recent climb to $106.25 followed its Q2 2026 earnings report, pushing it above the new target. Despite a …

AbCellera Biologics Inc. Stock 12‑Month Price Target Raised to $10.75, Implies 82% Upside

AbCellera Biologics Inc. (ABCL) has seen its average 12-month price target raised to $10.75 by 8 analysts, up from $10.50, with individual forecasts ranging from $7 to $13. This updated target suggests an 82% potential upside based on the August 5th closing price. The …

Renaissance Technologies LLC Sells 333,000 Shares of FuelCell Energy, Inc. $FCEL

Renaissance Technologies LLC reduced its stake in FuelCell Energy, Inc. (NASDAQ:FCEL) by 27.3%, selling 333,000 shares in the first quarter but still holding 886,600 shares valued at approximately $5.8 million. Despite some analyst upgrades and raised price targets, the company reported a quarterly loss …

Millicom International Cellular SA stock hits 52-week high at 101.99 USD

Millicom International Cellular SA (TIGO) stock has reached a 52-week high of $101.99, currently trading at $102.01. Despite an InvestingPro analysis suggesting it is slightly overvalued, the company has shown strong performance with a 151.42% 1-year total return and a 73.67% year-to-date gain. Recent …

Public Employees Retirement System of Ohio Decreases Stock Holdings in Cellebrite DI Ltd. $CLBT

The Public Employees Retirement System of Ohio significantly reduced its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 80.5% in the first quarter, selling over 110,000 shares. Despite this reduction, other institutional investors have increased their positions, and analysts maintain a "Moderate Buy" consensus rating …

Earnings call transcript: AbCellera misses Q2 2026 estimates as revenue drops

AbCellera Biologics Inc. reported a wider-than-expected Q2 2026 loss and revenue significantly below analyst estimates, with revenue dropping by 76% year-over-year. The company attributed the revenue decline to a strategic shift from external collaborations to internal drug development, leading to increased R&D spending. Despite …

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABCL) 2026-08-06

This document is AbCellera Biologics' 10-Q filing for its Q2 2026 earnings report. A 10-Q is a comprehensive quarterly report filed by public companies with the SEC, containing unaudited financial performance. It provides a detailed overview of the company's financial condition and results of …

MILLICOM INTL CELLULAR SA ($TIGO) Releases Q2 2026 Earnings

MILLICOM INTL CELLULAR SA ($TIGO) has released its Q2 2026 earnings, reporting $0.64 earnings per share and revenue of $2,179,000,000, both surpassing analyst estimates. The article also details recent insider trading activity, showing 5 sales and no purchases in the last 6 months, and …

Millicom Sets $1.50 Dividend for Two Payments in 2027

Millicom (NASDAQ: TIGO) has raised its 2026 Equity Free Cash Flow (EFCF) target to around $1.1 billion and reduced its year-end leverage target to below 2.5x due to strong performance. The company also declared an interim dividend of $1.50 per share, to be paid …

Millicom (Tigo) raises 2026 Financial Guidance and declares $1.50 per share interim dividend

Millicom (Tigo) has increased its 2026 Equity Free Cash Flow (EFCF) target to around $1.1 billion and lowered its year-end leverage target to below 2.5x, citing strong year-to-date performance. In response to this enhanced financial outlook, the company's Board of Directors declared an interim …

Millicom Approves Extra $1.50 Dividend, Payable in 2027

Cellectis (NASDAQ: CLLS) reports H1 2026 loss but $169M cash runway

ImmuCell (ICCC) Expected to Release Earnings on Thursday

Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M

Cellectis (NASDAQ: CLLS) posts $39.6M H1 loss, holds $166.8M cash

Stifel Nicolaus Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

Lineage Cell Therapeutics Inc (LCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cellebrite DI (CLBT) Expected to Announce Quarterly Earnings on Thursday

Cellebrite DI (CLBT) is scheduled to report its Q2 2026 earnings before market open on Thursday, August 13th, with analysts anticipating earnings of $0.0616 per share and revenue of $131.8740 million. The stock opened at $15.64, trading within a 52-week range of $11.02 to …

Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Rating of "Moderate Buy" by Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $21.40. This rating is based on five buy ratings and one hold rating from six research firms. The company's stock opened at $15.64, and …

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) completed enrollment for the phase 2 study of ABCL-635 in treating …

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This …

Is AbCellera Biologics Inc (ABCL) Facing Headwinds After Q2 Earnings Miss? GF Score: 59/100

AbCellera Biologics Inc (ABCL) reported a significant Q2 2026 earnings miss with revenues of $4.1 million against an estimated $7.78 million and a net loss of $55.4 million. Despite the financial shortfall, the company maintains a strong liquidity position of over $565 million in …

Abcellera Biologics earnings missed, revenue fell short of estimates